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Abstract. Cardiovascular diseases are the leading cause of death worldwide.
Loss or dysfunction of cardiomyocytes is associated with many forms of heart
disease. The adult mammalian heart has a limited regenerative ability after
damage, leading to the formation of ﬁbrotic scar tissues, hypertrophy, contractile
dysfunction and ultimately, organ failure. In contrast, neonatal mammalian
cardiomyocytes retain a signiﬁcant replenishing potential briefly after birth.
There is increasing enthusiasm to grow neonatal cardiomyocytes in 3D culture
systems to artiﬁcially restore heart function. Various scaffolds and matrices are
available, but the molecular and cellular mechanisms underlying proliferation
and differentiation of neonatal mammalian cardiomyocytes are not very well
understood. Here, we utilize a systematic strategy to analyze the extensive
genome-scale gene expression proﬁles of two different 3D constructs. We
present a comprehensive comparison that may help improve the protocols for
growing cardiomyocytes in a 3D culture system.
Keywords: Cardiomyocytes  Regeneration  3-D culture system  Gene
expression  Bioinformatics
1 Introduction
Cardiovascular diseases (CVDs) are the number one cause of death throughout the
world [1], with the loss or dysfunction of cardiomyocytes being the key event leading
to the formation of ﬁbrotic scar tissues, pathological hypertrophy, contractile
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dysfunction, and eventually resulting in heart failure [2]. In 2008, CVDs already
account for 30 % of the total global deaths [1]. It is estimated that by 2030, more than
23 million people worldwide would die from CVDs [3].
Unfortunately, current pharmacological or surgical therapies for CVDs can slow the
disease progression, but are unable to fully ameliorate cardiomyocyte loss or dys-
function [4]. Despite improvements in treatment, patients are still susceptible to an
increased risk of chronic cardiac failure as scarring develops after injury [5]. The high
disease burden, both from the perspectives of the healthcare system and the patients’
quality of life, demands new therapeutic strategies to treat CVDs.
Advances in stem cell research and cell biology techniques have provided a wide
variety of approaches to regenerate the heart from progenitor and cardiomyocytes
derived from embryonic, neonatal, and adult cells. Though adult cardiomyocytes have
been shown to have regenerative ability after injury, proliferation and differentiation
occur at a much lower rate compared to embryonic and neonatal cells [6]. It is still
unclear how and whether efﬁcient cardiac regeneration can be stimulated and regulated
in the adult mammalian heart.
In contrast, signiﬁcant cardiac regeneration has been observed in the neonatal
mammalian heart. In the mouse heart, surgical amputation of the ventricular apex has
been shown to initiate cardiomyocyte proliferation, suggesting that the neonatal heart is
capable of endogenous regenerative response [7]. However, such event only sustains
for a brief period after birth. The cellular and molecular underpinnings of postnatal cell
cycle arrest in cardiomyocytes and loss of cardiac regenerative capacity in the mam-
malian heart still remain elusive. Enhanced understanding of these key molecular
events may offer novel insights for the development of ways to manipulate or extend
the neonatal cardiac regenerative potential into adulthood.
In regenerative cell biology research, 3D cultures are gaining attention since they
allow for the generation of 3D architecture that resembles more closely to the native
environment of the tissue. Indeed, cells cultured in 3D and 2D conditions have been
shown to differ in gene expression proﬁle and phenotype [8]. Important markers of
development and response to hormonal stimulation are more readily observed in 3D
systems. 3D cultures have also been found to activate cell proliferation more efﬁciently
compared to 2D designs [9]. It appears that 2D cultures may not be as flexible for
manipulations or modulations, and thus, lack translational potential.
Owing to its increasing popularity in regenerative medical research, 3D constructs
are now available with variable physical, chemical, and biological properties that can
be manipulated to suit different purposes. For example, extracellular matrix prepared
from decellularized cardiac tissue could be fabricated into 3D scaffolds and matrices,
and injected to treat postmyocardial infarction injury [10–12]. Hydrogels and synthetic
biodegradable materials can also be fabricated to create customized patterns and
constructs [13, 14]. In fact, hydrogels have been combined with cell agents to suc-
cessfully improve repair of cardiac function post injury [15–18].
Similar to the difference between 3D and 2D culture systems, different properties of
3D constructs may result in varying levels of success in cardiac tissue regeneration.
We have compared among two 3D systems, PuraMatrixTM (BD Bioscience, U.S.A.)
and Go-Matrix (Bio-Byblos Biomedical Co., Ltd., Taiwan), and the traditional 2D-cell
culture system. The PuraMatrixTM construct is composed of peptide hydrogel with
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irregular pore arrangements, whereas Go-Matrix is made of gelatin from porcine skin
with regular pore patterns. Compared to the more normal looking 2D-culture system
and Go-Matrix, we observe irregular formation of muscle ﬁbers that resembles myo-
cardial ﬁbrosis, as well as abnormal beating of the cardiac tissue manufactured from
PuraMatrixTM (unpublished results).
In the present study, we set to compare the gene expression differences between
PuraMatrixTM and Go-Matrix with microarray technology, using the 2D architecture as
a baseline reference. The reason for including the 2D culture is that we have repeatedly
and successfully generated cardiac tissues from this system. The next step in our
research is to construct a 3D model that holds much more promises for clinical
applications. Therefore, the 2D construct serves as a good normalization control for our
analysis.
Microarray gene expression proﬁles comparing three different cell culture models,
with each probe on the bio-chip repeatedly targeting (at least 10 times) each of the
approximately 25,000 transcripts in the mouse genome. Such proﬁles represent a big
dataset with great complexity and require a systematic pipeline combining the available
bioinformatics tools to extract important biological meanings.
Here, we present an integrative system flow involving various tools for the analysis
of gene expression differences between PuraMatrixTM and Go-Matrix. These resources
are integrated on the WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) [19] and
mirWalk [20], and include curated information from Gene Ontology (GO) [21], Kyoto
Encyclopedia of Genes and Genomes (KEGG) [22], Pathway Commons [23], Wiki-
Pathway [24], miRBase [25], Diana-microT [26], miRanda [27], miRDB [28], PicTar
[29], PITA [30], RNA22 [31], and TargetScan [32]. We believe a combinatorial
analysis utilizing publicly available bioinformatics tools should provide a better
overview of the signiﬁcance in the experiment design. Identifying the biological sig-
niﬁcance underlying the molecular differences between the two different 3D cell culture
systems may help facilitate improvements in protocols for mending the “broken” heart.
2 Methods and Materials
2.1 System Flow
The system flow of our study is depicted in Fig. 1. Gene expression microarray
experiment is performed to identify differentially expressed transcripts among two 3D
cell culture systems, PuraMatrixTM and Go-Matrix, with the traditional 2D culture as a
normalization control. Differentially expressed were categorized into up- and down-
regulated genes, and divided into PuraMatrix- and Go-Matrix-speciﬁc groups. The
differentially expressed genes are subsequently subjected to bioinformatics analysis
WebGestalt [19] and mirWalk [20].
2.2 Cardiomyocyte Isolation
All procedures were approved by the Institutional Animal Care and Use Committee of
the Far-Eastern Memorial Hospital. Neonatal B6 mice were sacriﬁced by de-capitation
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on postnatal day 3. 25 neonatal mice underwent the surgical procedures for cardio-
myocyte isolation. The hearts were quickly excised and transferred into ice-cold
phosphate buffer saline (PBS, Sigma), and quickly minced in a solution of colla-genase
A + B solution (10 mg/ml in PBS). Cells in the supernatants were resuspended in
claycomb medium with 10 % fetal bovine serum (FBS, Gibco) and plated for 1.5 h at
37 °C. The attached ﬁbroblasts and endothelial cells were removed and the cardio-
myocytes were isolated in the suspension solution.
2.3 Cell Seeding of Constructs
Cardiomyocytes were cultured on gelatin/ﬁbronectin-coated tissue-culture flasks in
claycomb medium at 37 °C in a CO2 incubator. Cells harvested and cultured in this
method served as the 2D control group. To prepare PuraMatrixTM, 1 % stock solution
was mixed with 20 % sucrose (Sigma–Aldrich, Sweden AB) and DMEM containing
Ca2+ and Mg2+ in a 2:1:1 ratio, giving 0.5 % hydrogel. Cardiomyocytes were detached
from the culture flasks with trypsin/EDTA, concentrated in claycomb medium and
immersed with PuraMatrixTM peptide hydrogel. Go-Matrix is a gelatin scaffold ﬁxed
on tissue-culture flasks. The claycomb medium containing cardiomyocytes was drop-
ped onto the dry Go Matrix. In total, 106 cells were cultured in each group.
2.4 RNA Isolation
RNA was isolated from harvested cardiomyocyte cells. RNA quality was determined
by an OD 260/280 ratio ≥ 1.8, and OD 260/230 ratio ≥ 1.5 on a spectrophotometer and
by the intensity of the 18S and 28S rRNA bands on a 1 % formaldehydeagarose gel.
RNA quantity was detected by a spectrophotometer. RNA integrity was examined on
an Agilent Bioanalyzer. RNA with a 2100 RIN (RNA integrity number) ≥ 6.0 and 28S/
18S > 0.7 was subjected to microarray analysis.
Fig. 1. System flow of our wet bench and bioinformatics analyses.
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2.5 Gene Expression Analysis
Total RNA samples from 25 mice in each construct are pooled and subsequently sub-
jected to SurePrint G3 Mouse GE 8x60 K Microarray (Agilent Technologies, U.S.A.).
Data are analyzed using R/Bioconductor. PuraMatrixTM and Go-Matrix expression
proﬁles were normalized against that of the cardiomyocytes prepared from the traditional
2D cell culture system. Genes showing signiﬁcant differential expression between nor-
malized PuraMatrixTM and Go-Matrix (absolute value of log2 ratio > 1.0, FDR < 0.05)
were categorized into PuraMatrixTM -speciﬁc down- and up-regulated genes, and Go-
Matrix-speciﬁc down- and up-regulated genes.
2.6 Bioinformatics Analysis
A flow chart describing our bioinformatics analysis is given in Fig. 2. Differentially
expressed genes were used as input for the bioinformatics analysis of gene ontology
(GO) enrichment analysis and pathway enrichment analysis. Multiple testing bias is
adjusted by a Bonferroni threshold of p < 0.05. These analyses are performed on the
open analytical platform in WebGestalt [19], which integrates GO [21], KEGG [22],
Pathway Commons [23], and WikiPathways [24]. microRNA target prediction analysis
is conducted in mirWalk [20], which, in addition to the developers’ own analytical
algorithms, also makes comparisons with other microRNA databases, including miR-
Base [25], Diana-microT [26], miRanda [27], miRDB [28], PicTar [29], PITA [30],
RNA22 [31], and TargetScan [32].
3 Results and Discussions
In total, there are 516 up-regulated and 338 down-regulated genes, and 401 up-regulated
and 292 down-regulated genes speciﬁc to the PuraMatrixTM and Go-Matrix expression
proﬁles, respectively (Fig. 3). It appears that the Go-Matrix expression proﬁle may be
Fig. 2. Bioinformatics analysis workflow
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more similar to the traditional 2D culture system. For both 3D constructs, the top three
most enriched biological processes are: biological regulation, metabolic process, and
response to stimulus. The top three most important cellular components include the
membrane, nucleus, and macromolecular complex. For molecular functions, both
expression proﬁles are enriched in protein binding, ion binding, and metabolite binding.
PuraMatrixTM and Go-Matrix expression proﬁles appear to be similar in muscle
contraction pathways, though the gene expression patterns are different. In particular,
the striated muscle contraction pathway that is enriched in both PuraMatrixTM and
Go-Matrix gene list. However, the two 3D cell culture systems differ in the genes that
are differentially expressed in this pathway.
Though similar in some pathways, PuraMatrixTM and Go-Matrix expression pro-
ﬁles appear to be enriched in different types of cellular pathways. For instance, most of
the differentially expressed genes in the PuraMatrixTM construct seem to belong to
muscle contraction and cell adhesion related pathways (Table 1). In contrast, Go-
Matrix-speciﬁc differentially expressed genes are enriched in pathways involving
membrane receptor interactions.
Cell culture observations indicate that the PuraMatrixTM cell culture system tends to
generate tissue with abnormal muscle ﬁber arrangements and contractions (unpublished
results). This is consistent with our gene expression proﬁle analysis in that most of the
differentially expressed genes in the PuraMatrixTM design belong to cardiomyopathy
pathways. For example, among the list of PuraMatrixTM-speciﬁc up-regulated genes
involved in dilated cardiomyopathy, the ryanodine receptor 2 (Ryr2) gene, when
silenced by RNAi, protects rat cardiomyocytes from simulated ischemia-induced
injury [33]. The Pln (phospholabam) gene, when deleted or suppressed, is known to
restore normal cardiomyocyte contraction and slow the progression towards cardio-
myopathy [34]. This suggests that the observed phenotype and gene expression changes
associated with the PuraMatrixTM construct of cardiomyoctes may serve as a potential
basis for the future development of a cardiomyopathy related disease model.
In contrast, the differentially expressed genes in the Go-matrix seem to be related to
the development of cardiac cells and the establishment of cell-cell contact (Table 1).
This corresponds to the ordered arrangements of muscle ﬁbers and regular muscle
contractions of the Go-Matrix cardiomyocyte culture (unpublished results). The
enrichment analysis result is also consistent with similar ﬁndings in fetal sheep, in
which neuroactive-ligand-receptor interaction, cytokine-cytokine receptor interaction,
Up-regulated Down-regulated
PuraMatrix
GoMatrix
516 134 401 338 100 292
Fig. 3. Number of Differentially expressed genes from the PuraMatrixTM and Go-Matrix
expression proﬁles
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complement and coagulation cascades, etc. were associated cardiogenesis [35].
In particular, the Notch signaling pathway has been implicated in development of
cardiac neural crest cells and heart valves [36].
Interestingly, differentially expressed genes in both PuraMatrixTM and Go-matrix
proﬁles are enriched in the striated muscle contraction pathway, though these genes
play differing roles in this particular process (Fig. 4). This indicates that differences in
the modulation of gene expression have speciﬁc effect on the muscle contraction
phenotype. Such differences may contribute to the phenotypic variations between the
cardiomyocytes grown in these two culture systems.
The interactions among the differentially expressed genes involved in the striated
muscle contraction pathway may reveal the molecular underpinnings of the differences
in muscle contraction between cardiomyoctyes constructed by PuraMatrixTM and Go-
Matrix. Protein-interaction and microRNA target analysis suggest that three genes
would be strong potential candidates for further functional study of cardiac develop-
ment. These genes are Myh6 (myosin, heavy polypeptide 6, cardiac muscle, alpha),
which is expressed in the atria and associated with congenital heart defects [37]; Tnnc1
(troponin C type 1), which plays a regulatory role in the beating of the early developing
heart [38]; Des (desmin), which is an intermediate ﬁlament gene important for muscle
architecture [39].
Our results suggest that that Myh6, Tnnc1, and Des are likely interacting with each
other, as well as with other important molecular signatures of the cardiac contraction
pathway (Fig. 5). Furthermore, their expression may be regulated by several
microRNAs that have been implicated to play important roles in cardiac function. For
instance, the mir-29 family is responsible for modulating the development of cardiac
Table 1. List of top 3 most enriched pathways in PuraMatrixTM and Go-Matrix expression
proﬁles as identiﬁed by KEGG and WikiPathway.
PuraMatrixTM enriched pathways Go-Matrix enriched pathways
KEGG (up-regulation)
Dilated cardiomyopathy Neuroactive-ligand-receptor interaction
Hypertrophic cardiomyopathy Cytokine-cytokine receptor interaction
Pathways in cancer Complement and coagulation cascades
KEGG (down-regulation)
Vascular smooth muscle contraction Axon guidance
Neuroactive-ligand-receptor interaction Notch signaling pathway
Protein digestion and absorption Melanogenesis
WikiPathway (up-regulation)
Striated muscle contraction Complement and coagulation cascades
Focal adhesion Non-odorant G-protein coupled receptors
PPAR signaling pathway Striated muscle contraction
WikiPathway (down-regulation)
Striated muscle contraction Delta-Notch signaling pathway
Integrin-mediated cell adhesion Cholesterol biosynthesis
Focal adhesion Complement and coagulation cascades
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ﬁbrosis after injury [40]. In addition, mir-208a is known to be a regulator of cardiac
stress response [41]. The interaction network presented in Fig. 5 may represent a
potential modulatory mechanism underlying the differences the in muscle contraction
phenotype between PuraMatrixTM and Go-Matrix.
Tmod1
Dmd
Tnnt3 Tnnti3
Tnnc1
Myl1
Myl4
Tcap
Mybpc3
Myh6
Myh8
Casq2
Myom2
Acta1
Acta2
Mybpc2
Des
Tnnt1
Actg1
Up-regulated in Go-Matrix
Up-regulated in PuraMatrixTM
Down-regulated in PuraMatrixTM
Fig. 4. PuraMatrixTM-speciﬁc and Go-Matrix-speciﬁc differentially expressed genes involved in
the striated muscle contraction pathway
mmu-miR1
mmu-miR133a
mmu-miR133bmmu-miR125a
mmu-miR29a
mmu-miR208a
Fig. 5. Protein interaction network showing the interaction among Myh6, Tnnc1, Des with other
genes and corresponding validated regulatory microRNAs from the striated muscle contraction
pathway
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4 Conclusion
3D cell culture systems are gaining attention in regenerative medical research. These
constructs can be manipulated to suit different purposes, either for understanding
development and disease mechanisms, or establishing a disease model. The ways in
which these systems can be manipulated is of particular interest to regenerative med-
icine. Here, we present a systematic pipeline, integrating a wide variety of bioinfor-
matics tools, to extract important biological meanings from the genome-scale
differences between two 3D systems utilized for cardiomyocyte culturing. Our analysis
presents a preliminary picture of the signiﬁcant pathways and interactions associated
with cardiomyocyte development in 3D. Our ﬁndings may have special implications
for the future establishment of a better model for murine neonatal heart regeneration.
References
1. Organization, W.H.: Global status report on noncommunicable diseases 2010. World Health
Organization (2011)
2. Kajstura, J., Urbanek, K., Perl, S., Hosoda, T., Zheng, H., Ogorek, B., Ferreira-Martins, J.,
Goichberg, P., Rondon-Clavo, C., Sanada, F., D’Amario, D., Rota, M., Del Monte, F., Orlic,
D., Tisdale, J., Leri, A., Anversa, P.: Cardiomyogenesis in the adult human heart. Circ. Res.
107, 305–315 (2010)
3. Mathers, C.D., Loncar, D.: Projections of global mortality and burden of disease from 2002
to 2030. PLoS Med. 3, e442 (2006)
4. Steinhauser, M.L., Lee, R.T.: Regeneration of the heart. EMBO Mol. Med. 3, 701–712
(2011)
5. Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., El
Nakadi, B., Banovic, M., Beleslin, B., Vrolix, M., Legrand, V., Vrints, C., Vanoverschelde,
J.L., Crespo-Diaz, R., Homsy, C., Tendera, M., Waldman, S., Wijns, W., Terzic, A.:
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell
therapy in heart failURE) multicenter randomized trial with lineage-speciﬁed biologics.
J. Am. Coll. Cardiol. 61, 2329–2338 (2013)
6. Hsieh, P.C.H., Segers, V.F.M., Davis, M.E., MacGillivray, C., Gannon, J., Molkentin, J.D.,
Robbins, J., Lee, R.T.: Evidence from a genetic fate-mapping study that stem cells refresh
adult mammalian cardiomyocytes after injury. Nat. Med. 13, 970–974 (2007)
7. Porrello, E.R., Mahmoud, A.I., Simpson, E., Hill, J.A., Richardson, J.A., Olson, E.N.,
Sadek, H.A.: Transient regenerative potential of the neonatal mouse heart. Science 331,
1078–1080 (2011)
8. Akins Jr., R.E., Rockwood, D., Robinson, K.G., Sandusky, D., Rabolt, J., Pizarro, C.: Three-
dimensional culture alters primary cardiac cell phenotype. Tissue Eng. Part A 16, 629–641
(2010)
9. Kellar, R.S., Landeen, L.K., Shepherd, B.R., Naughton, G.K., Ratcliffe, A., Williams, S.K.:
Scaffold-based three-dimensional human ﬁbroblast culture provides a structural matrix that
supports angiogenesis in infarcted heart tissue. Circulation 104, 2063–2068 (2001)
10. Singelyn, J.M., Christman, K.L.: Injectable Materials for the Treatment of Myocardial
Infarction and Heart Failure: The Promise of Decellularized Matrices. J. Cardiovasc. Transl.
3, 478–486 (2010)
762 J.T.-Y. Weng et al.
11. Godier-Furnemont, A.F.G., Martens, T.P., Koeckert, M.S., Wan, L., Parks, J., Arai, K.,
Zhang, G.P., Hudson, B., Homma, S., Vunjak-Novakovic, G.: Composite scaffold provides
a cell delivery platform for cardiovascular repair. Proc. Natl. Acad. Sci. U.S.A. 108,
7974–7979 (2011)
12. Singelyn, J.M., Sundaramurthy, P., Johnson, T.D., Schup-Magofﬁn, P.J., Hu, D.P., Faulk, D.
M., Wang, J., Mayle, K.M., Bartels, K., Salvatore, M., Kinsey, A.M., Demaria, A.N., Dib,
N., Christman, K.L.: Catheter-deliverable hydrogel derived from decellularized ventricular
extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function
post-myocardial infarction. J. Am. Coll. Cardiol. 59, 751–763 (2012)
13. Khademhosseini, A., Langer, R., Borenstein, J., Vacanti, J.P.: Microscale technologies for
tissue engineering and biology. Proc. Natl. Acad. Sci. U.S.A 103, 2480–2487 (2006)
14. Rane, A.A., Chuang, J.S., Shah, A., Hu, D.P., Dalton, N.D., Gu, Y., Peterson, K.L., Omens,
J.H., Christman, K.L.: Increased infarct wall thickness by a bio-inert material is insufﬁcient
to prevent negative left ventricular remodeling after myocardial infarction. PLoS ONE 6,
e21571 (2011)
15. Garbern, J.C., Minami, E., Stayton, P.S., Murry, C.E.: Delivery of basic ﬁbroblast growth
factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted
myocardium. Biomaterials 32, 2407–2416 (2011)
16. Lu, W.N., Lu, S.H., Wang, H.B., Li, D.X., Duan, C.M., Liu, Z.Q., Hao, T., He, W.J., Xu, B.,
Fu, Q., Song, Y.C., Xie, X.H., Wang, C.Y.: Functional improvement of infarcted heart by
co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue
Eng. Part A 15, 1437–1447 (2009)
17. Huang, N.F., Yu, J.S., Sievers, R., Li, S., Lee, R.J.: Injectable biopolymers enhance
angiogenesis after myocardial infarction. Tissue Eng. 11, 1860–1866 (2005)
18. Davis, M.E., Motion, J.P., Narmoneva, D.A., Takahashi, T., Hakuno, D., Kamm, R.D.,
Zhang, S., Lee, R.T.: Injectable self-assembling peptide nanoﬁbers create intramyocardial
microenvironments for endothelial cells. Circulation 111, 442–450 (2005)
19. Wang, J., Duncan, D., Shi, Z., Zhang, B.: WEB-based GEne SeT AnaLysis Toolkit
(WebGestalt): update 2013. Nucleic Acids Res. 41, W77–W83 (2013)
20. Dweep, H., Sticht, C., Pandey, P., Gretz, N.: miRWalk–database: prediction of possible
miRNA binding sites by “walking” the genes of three genomes. J. Biomed. Inform. 44,
839–847 (2011)
21. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P.,
Dolinski, K., Dwight, S.S., Eppig, J.T., Harris, M.A., Hill, D.P., Issel-Tarver, L., Kasarskis,
A., Lewis, S., Matese, J.C., Richardson, J.E., Ringwald, M., Rubin, G.M., Sherlock, G.:
Gene ontology: tool for the uniﬁcation of biology. The Gene Ontology Consortium. Nat.
Genet. 25, 25–29 (2000)
22. Kanehisa, M., Araki, M., Goto, S., Hattori, M., Hirakawa, M., Itoh, M., Katayama, T.,
Kawashima, S., Okuda, S., Tokimatsu, T., Yamanishi, Y.: KEGG for linking genomes to life
and the environment. Nucleic Acids Res. 36, D480–D484 (2008)
23. Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N.,
Bader, G.D., Sander, C.: Pathway Commons, a web resource for biological pathway data.
Nucleic Acids Res. 39, D685–D690 (2011)
24. Pico, A.R., Kelder, T., van Iersel, M.P., Hanspers, K., Conklin, B.R., Evelo, C.:
WikiPathways: Pathway editing for the people. PLoS Biol. 6, 1403–1407 (2008)
25. Grifﬁths-Jones, S., Saini, H.K., van Dongen, S., Enright, A.J.: miRBase: tools for
microRNA genomics. Nucleic Acids Res. 36, D154–D158 (2008)
Comparative Analysis of 3D-Culture System for Murine Neonatal Heart Regeneration 763
26. Maragkakis, M., Reczko, M., Simossis, V.A., Alexiou, P., Papadopoulos, G.L., Dalamagas,
T., Giannopoulos, G., Goumas, G., Koukis, E., Kourtis, K., Vergoulis, T., Koziris, N., Sellis,
T., Tsanakas, P., Hatzigeorgiou, A.G.: DIANA-microT web server: elucidating microRNA
functions through target prediction. Nucleic Acids Res. 37, W273–W276 (2009)
27. Betel, D., Wilson, M., Gabow, A., Marks, D.S., Sander, C.: The microRNA.org resource:
targets and expression. Nucleic Acids Res. 36, D149–D153 (2008)
28. Wang, X.: miRDB: a microRNA target prediction and functional annotation database with a
wiki interface. RNA 14, 1012–1017 (2008)
29. Anders, G., Mackowiak, S.D., Jens, M., Maaskola, J., Kuntzagk, A., Rajewsky, N.,
Landthaler, M., Dieterich, C.: doRiNA: a database of RNA interactions in post-
transcriptional regulation. Nucleic Acids Res. 40, D180–D186 (2012)
30. Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., Segal, E.: The role of site accessibility in
microRNA target recognition. Nat. Genet. 39, 1278–1284 (2007)
31. Loher, P., Rigoutsos, I.: Interactive exploration of RNA22 microRNA target predictions.
Bioinformatics 28, 3322–3323 (2012)
32. Grimson, A., Farh, K.K.H., Johnston, W.K., Garrett-Engele, P., Lim, L.P., Bartel, D.P.:
MicroRNA targeting speciﬁcity in mammals: Determinants beyond seed pairing. Mol. Cell
27, 91–105 (2007)
33. Guo, Z., Wang, S., Jiao, Q., Xu, M., Gao, F.: RNAi targeting ryanodine receptor 2 protects
rat cardiomyocytes from injury caused by simulated ischemia-reperfusion. Biomed.
Pharmacotherapie 64, 184–190 (2010)
34. Hoshijima, M., Ikeda, Y., Iwanaga, Y., Minamisawa, S., Date, M.O., Gu, Y., Iwatate, M.,
Li, M., Wang, L., Wilson, J.M., Wang, Y., Ross Jr., J., Chien, K.R.: Chronic suppression of
heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo
cardiac rAAV gene delivery. Nat. Med. 8, 864–871 (2002)
35. Cox, L.A., Glenn, J.P., Spradling, K.D., Nijland, M.J., Garcia, R., Nathanielsz, P.W., Ford,
S.P.: A genome resource to address mechanisms of developmental programming:
determination of the fetal sheep heart transcriptome. J. Physiol-London 590, 2873–2884
(2012)
36. Niessen, K., Karsan, A.: Notch signaling in cardiac development. Circ. Res. 102, 1169–1181
(2008)
37. Granados-Riveron, J.T., Ghosh, T.K., Pope, M., Bu’Lock, F., Thornborough, C., Eason, J.,
Kirk, E.P., Fatkin, D., Feneley, M.P., Harvey, R.P., Armour, J.A., David Brook, J.: Alpha-
cardiac myosin heavy chain (MYH6) mutations affecting myoﬁbril formation are associated
with congenital heart defects. Hum. Mol. Genet. 19, 4007–4016 (2010)
38. Stoutamyer, A., Dhoot, G.K.: Transient expression of fast troponin C transcripts in
embryonic quail heart. J. Muscle Res. Cell Motil. 26, 237–245 (2005)
39. Sam, M., Shah, S., Friden, J., Milner, D.J., Capetanaki, Y., Lieber, R.L.: Desmin knockout
muscles generate lower stress and are less vulnerable to injury compared with wild-type
muscles. Am. J. Physiol-Cell Ph. 279, C1116–C1122 (2000)
40. van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, W.S.,
Hill, J.A., Olson, E.N.: Dysregulation of microRNAs after myocardial infarction reveals a
role of miR-29 in cardiac ﬁbrosis. Proc. Natl. Acad. Sci. U.S.A. 105, 13027–13032 (2008)
41. Callis, T.E., Pandya, K., Seok, H.Y., Tang, R.H., Tatsuguchi, M., Huang, Z.P., Chen, J.F.,
Deng, Z.L., Gunn, B., Shumate, J., Willis, M.S., Selzman, C.H., Wang, D.Z.: MicroRNA-
208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest. 119,
2772–2786 (2009)
764 J.T.-Y. Weng et al.
